Teva and Apotex must wait until at least early January to launch their generic versions of Vanda Pharmaceuticals’ landmark sleep disorder drug, Hetlioz (tasimelteon) capsules, despite a decisive patent infringement victory in a US district court.
Following Delaware district judge Colm Connolly’s 13 December ruling, finding in favor of Teva and Apotex on their challenges for all four Hetlioz patents at-issue, the court has
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?